Business Description
IN8bio Inc
NAICS : 325412
SIC : 2834
ISIN : US45674E2081
Share Class Description:
INAB: Ordinary SharesTotal Employee Number:
18Description
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 9.32 | |||||
Equity-to-Asset | 0.87 | |||||
Debt-to-Equity | 0.1 | |||||
Debt-to-EBITDA | -0.14 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 53.4 | |||||
3-Year EPS without NRI Growth Rate | 52.3 | |||||
3-Year FCF Growth Rate | 58.2 | |||||
3-Year Book Growth Rate | -53.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 42.81 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 29.58 | |||||
9-Day RSI | 35.34 | |||||
14-Day RSI | 39.01 | |||||
3-1 Month Momentum % | 14.97 | |||||
6-1 Month Momentum % | -24.22 | |||||
12-1 Month Momentum % | -21.76 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 10.5 | |||||
Quick Ratio | 10.5 | |||||
Cash Ratio | 10.17 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -128.6 | |||||
Shareholder Yield % | -160.76 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -102.44 | |||||
ROA % | -82.84 | |||||
ROIC % | -289.79 | |||||
3-Year ROIIC % | -128.72 | |||||
ROC (Joel Greenblatt) % | -405.75 | |||||
ROCE % | -94.85 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.59 | |||||
Price-to-Tangible-Book | 0.59 | |||||
EV-to-EBIT | 0.34 | |||||
EV-to-EBITDA | 0.38 | |||||
EV-to-FCF | 0.45 | |||||
| Price-to-Net-Current-Asset-Value | 0.7 | |||||
| Price-to-Net-Cash | 0.73 | |||||
Earnings Yield (Greenblatt) % | 294.12 | |||||
FCF Yield % | -111.53 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:INAB
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
IN8bio Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.856 | ||
| Beta | 0.3127 | ||
| 3-Year Sharpe Ratio | -1.21 | ||
| 3-Year Sortino Ratio | -1.37 | ||
| Volatility % | 68.58 | ||
| 14-Day RSI | 39.01 | ||
| 14-Day ATR ($) | 0.094141 | ||
| 20-Day SMA ($) | 1.48149 | ||
| 12-1 Month Momentum % | -21.76 | ||
| 52-Week Range ($) | 1.17 - 2.73 | ||
| Shares Outstanding (Mil) | 9.59 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
IN8bio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
IN8bio Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 131 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 40 days | ||
| Guidance call for 2026 | 2026-05-21 09:00 | 1.57 (+8.28%) | ||
| General meeting for 2026 | 2026-05-07 09:00 | 1.58 (-5.95%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 1.58 (-5.95%) | ||
| Annual report for 2025 | 2026-03-12 | 1.99 (+10.56%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-12 | 1.99 (+10.56%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-02 09:50 | 1.70 (+0.59%) | ||
| IO360deg Conference | 2026-02-12 13:20 | 1.99 (+3.65%) | ||
| Noble Emerging Growth Virtual Equity Conference | 2026-02-05 15:00 | 1.96 (-2.97%) |
Show
Entries
IN8bio Inc Frequently Asked Questions
What is IN8bio Inc(INAB)'s stock price today?
The current price of INAB is $1.36. The 52 week high of INAB is $2.73 and 52 week low is $1.17.
When is next earnings date of IN8bio Inc(INAB)?
The next earnings date of IN8bio Inc(INAB) is 2026-08-07 Est..
Does IN8bio Inc(INAB) pay dividends? If so, how much?
IN8bio Inc(INAB) does not pay dividend.
Guru Commentaries on NAS:INAB
No articles.
Articles on IN8bio Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers